Search Within

Weinberg Fellows

  1. "Clinical Lymphoma, Myeloma and Leukemia"
Formats
  1. Meeting Abstract (18)
  2. Journal Article (1)
Groups
  1. Department of Medicine (19)
  2. Hematology-Oncology Fellows (19)
  3. Center for Hematologic Malignancies (18)
  4. Hematologic Malignancies, Division of (18)
  5. GME, Medicine (14)
  6. Graduate Medical Education (14)

More Groups

People
  1. David Chung (13)
  2. Heather Landau (13)
  3. Ross Firestone (13)
  4. Saad Usmani (13)
  5. Sergio Giralt (13)
  6. Alexander Lesokhin (12)

More People

Years
  1. 2024 (10)
  2. 2023 (4)
  3. 2022 (1)
  4. 2017 (1)
  5. 2016 (2)
  6. 2015 (1)
Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (19)
Publishers
  1. Elsevier Inc. (19)

Results (19)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Defining the rates of cytokine release syndrome associated with Talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Increased WEE1 expression is predictive of short progression-free survival, independent of standard prognostic factors in multiple myeloma
    Meeting Abstract

    Simhal, A.; Firestone, R.; Oh, J. H.; Norton, L.; Usmani, S.; Deasy, J.; Maclachlan, K.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Meeting Abstract

    Maclachlan, K.; Shekarkhand, T.; Farzana, T.; Costa, B.; Firestone, R.; Jurgens, E.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
    Meeting Abstract

    Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Incidence and clinical impact of acute kidney injury: A comparison of CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B.; Farzana, T.; Jurgens, E.; Firestone, R.; Nath, K.; Chung, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • CMV reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R.; Miller, K.; Costa, B.; Rajeeve, S.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Rajeeve, S.; Jurgens, E.; Nishimura, N.; Farzana, T.; Firestone, R.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Tan, C.; Shekarkhand, T.; Firestone, R.; Jurgens, E.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; Rajeeve, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Maintenance therapy cessation for multiple myeloma patients with three-year sustained mrd negative remissions
    Meeting Abstract

    Korde, N.; Hassoun, H.; Landau, H.; Hamid, S.; Derkach, A.; Hultcrantz, M.; Mailankody, S.; Tan, C.; Shah, U.; Maclachlan, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save